Olema Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | ScheduleForm | File Number | Exhibit | FilingDate |
| 3.1 | Amended and Restated Certificate of Incorporation. | 8‑K | 001‑39712 | 3.1 | 11/23/2020 |
| 3.2 | Amended and Restated Bylaws. | 8‑K | 001‑39712 | 3.1 | 12/16/2022 |
| 10.1 | Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy. | 10-Q | 001‑39712 | 10.3 | 05/12/2026 |
| 10.2¥ | Lease Agreement, dated April 27, 2026, between KR Oyster Point II, LLC and Olema Pharmaceuticals, Inc. | 10-Q | 001‑39712 | 10.4 | 05/12/2026 |
| 10.3* | Fourth Amendment to Loan and Security Agreement, dated July 1, 2026, between Silicon Valley Bank and Olema Pharmaceuticals, Inc. | ||||
| 31.1* | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1*† | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | ||||
| 104 | Cover page formatted as Inline XBRL and contained in Exhibit 101 | ||||
- Filed herewith.
† The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act, irrespective of any general incorporation language contained in any such filing.
¥ Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the Registrant has determined that the omitted information is the type that the Registrant customarily and actually treats as private or confidential and is not material.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Olema Pharmaceuticals, Inc. | ||
| Date: August 10, 2026 | By: | /s/ Sean Bohen, M.D., Ph.D. |
|---|---|---|
| Sean Bohen, M.D., Ph.D. | ||
| President and Chief Executive Officer(Principal Executive Officer and Principal Financial Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.